近10年磁共振成像在帕金森黑质病变中的研究进展

张 树贤, 王 红*
新疆医科大学第二附属医院 医学影像中心 乌鲁木齐 830000

摘要

摘要：多巴胺能黑质纹状体系统受损是PD的核心病理改变，主要的特征为位于中脑黑质致密部处小体的神经元退行性变及铁异常沉积。最近的研究发现神经黑色素敏感成像、酰胺质子转移成像、磁敏感成像等可以作为影像标志物，显示PD患者和健康人的黑质结构并达到识别、诊断早期PD的效果。但另一方面，在PD诊断与鉴别诊断中，仅基于临床的症状诊断难以完全区分，而基于黑质的诊断效能不高。因此临床需要对帕金森病进行客观的诊断测试或生物影像标志物，有助于对PD患者的早期诊断及规范管理。

参考

[1]QI S, YIN P, WANG L, et al. Prevalence of Parkinson's

Disease: A Community-Based Study in China [J]. Mov Disord, 2021,

36(12): 2940-4.

[2]SCHRAG A, BEN-SHLOMO Y, QUINN N. How valid is the

clinical diagnosis of Parkinson's disease in the community? [J]. J

Neurol Neurosurg Psychiatry, 2002, 73(5): 529-34.

[3]SMOLDERS S, VAN BROECKHOVEN C. Genetic

perspective on the synergistic connection between vesicular transport,

lysosomal and mitochondrial pathways associated with Parkinson's

disease pathogenesis [J]. Acta Neuropathol Commun, 2020, 8(1): 63.

[4]CHAU M T, TODD G, WILCOX R, et al. Diagnostic accuracy

of the appearance of Nigrosome-1 on magnetic resonance imaging in

Parkinson's disease: A systematic review and meta-analysis [J].

Parkinsonism Relat Disord, 2020, 78: 12-20.

[5]VAN ZIJL P C, ZHOU J, MORI N, et al. Mechanism of

magnetization transfer during on-resonance water saturation. A new

approach to detect mobile proteins, peptides, and lipids [J]. Magn

Reson Med, 2003, 49(3): 440-9.

[6]ZHOU J, PAYEN J F, WILSON D A, et al. Using the amide

proton signals of intracellular proteins and peptides to detect pH

effects in MRI [J]. Nat Med, 2003, 9(8): 1085-90.

[7]米日班•买买提库尔班, 张树贤, 马景旭, et al. 酰胺质子

转移磁共振成像在帕金森病中的研究进展 [J]. 磁共振成像,

2023, 14(06): 94-8.[8]LI C, CHEN M, ZHAO X, et al. Chemical Exchange

Saturation Transfer MRI Signal Loss of the Substantia Nigra as an

Imaging Biomarker to Evaluate the Diagnosis and Severity of

Parkinson's Disease [J]. Front Neurosci, 2017, 11: 489.

[9]KITAO S, MATSUSUE E, FUJII S, et al. Correlation between

pathology and neuromelanin MR imaging in Parkinson's disease and

dementia with Lewy bodies [J]. Neuroradiology, 2013, 55(8): 947-53.

[10]杨俊强. 神经黑色素敏感的磁共振成像对诊断帕金森

病的应用价值 [D], 2021.

[11]柏福运, 高平. 神经黑色素敏感的MRI在帕金森病中的

应用进展 [J]. 国际医学放射学杂志, 2021, 44(02): 165-9.

[12]BIONDETTI E, GAURAV R, YAHIA-CHERIF L, et al.

Spatiotemporal changes in substantia nigra neuromelanin content in

Parkinson's disease [J]. Brain, 2020, 143(9): 2757-70.

[13]BIONDETTI E, SANTIN M D, VALABREGUE R, et al. The

spatiotemporal changes in dopamine, neuromelanin and iron

characterizing Parkinson's disease [J]. Brain, 2021, 144(10):

3114-25.

[14]SULZER D, CASSIDY C, HORGA G, et al. Neuromelanin

detection by magnetic resonance imaging (MRI) and its promise as a

biomarker for Parkinson's disease [J]. NPJ Parkinsons Dis, 2018, 4:

11.

[15]HATANO T, OKUZUMI A, KAMAGATA K, et al.

Neuromelanin MRI is useful for monitoring motor complications in

Parkinson's and PARK2 disease [J]. J Neural Transm (Vienna), 2017,

124(4): 407-15.

[16]WANG X, ZHANG Y, ZHU C, et al. The diagnostic value of

SNpc using NM-MRI in Parkinson's disease: meta-analysis [J].

Neurol Sci, 2019, 40(12): 2479-89.

[17]WOLTERS A F, HEIJMANS M, PRIOVOULOS N, et al.

Neuromelanin related ultra-high field signal intensity of the locus

coeruleus differs between Parkinson's disease and controls [J].

Neuroimage Clin, 2023, 39: 103479.

[18]LAKHANI D A, ZHOU X, TAO S, et al. Diagnostic utility of

7T neuromelanin imaging of the substantia nigra in Parkinson's

disease [J]. NPJ Parkinsons Dis, 2024, 10(1): 13.

[19]LOTFIPOUR A K, WHARTON S, SCHWARZ S T, et al.

High resolution magnetic susceptibility mapping of the substantia

nigra in Parkinson's disease [J]. J Magn Reson Imaging, 2012, 35(1):

48-55.

[20]BLAZEJEWSKA A I, SCHWARZ S T, PITIOT A, et al.

Visualization of nigrosome 1 and its loss in PD: pathoanatomical

correlation and in vivo 7 T MRI [J]. Neurology, 2013, 81(6): 534-40.

[21]HE N, GHASSABAN K, HUANG P, et al. Imaging iron and

neuromelanin simultaneously using a single 3D gradient echo

magnetization transfer sequence: Combining neuromelanin, iron and

the nigrosome-1 sign as complementary imaging biomarkers in early

stage Parkinson's disease [J]. Neuroimage, 2021, 230: 117810.

[22]ARIZ M, MARTINEZ M, ALVAREZ I, et al. Automatic

Segmentation and Quantification of Nigrosome-1 Neuromelanin and

Iron in MRI: A Candidate Biomarker for Parkinson's Disease [J]. J

Magn Reson Imaging, 2023.